Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia
NCT01918241 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2015-11-10
Summary
This study will assess the Efficacy and Safety of different doses of PEG-rhG-CSF and a single-dose of G-CSF in Preventing Chemotherapy-induced Neutropenia.
Conditions
Interventions
- DRUG
-
pegfilgrastim,30mcg/kg
Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
- DRUG
-
pegfilgrastim, 60mcg/kg
Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
- DRUG
-
pegfilgrastim, 100mcg/kg
Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
- DRUG
-
filgrastim, 5mcg/kg
At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
Sponsors & Collaborators
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
collaborator OTHER -
Peking University Cancer Hospital & Institute
collaborator OTHER -
Second Affiliated Hospital, School of Medicine, Zhejiang University
collaborator OTHER -
Jiangsu Cancer Institute & Hospital
collaborator OTHER -
The First Affiliated Hospital with Nanjing Medical University
collaborator OTHER -
Wuhan TongJi Hospital
collaborator OTHER -
The Affiliated Hospital of Inner Mongolia Medical University
collaborator OTHER -
Shandong Cancer Hospital and Institute
collaborator OTHER -
Changsha Central Hospital
collaborator OTHER -
Yangzhou No.1 People's Hospital
collaborator OTHER -
Subei People's Hospital of Jiangsu Province
collaborator OTHER -
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
lead INDUSTRY
Principal Investigators
-
Yuankai Shi · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-07-31
- Primary Completion
- 2016-01-31
Countries
- China
Study Locations
More Related Trials
-
A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
NCT02119715 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
NCT04009941 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients
NCT01637493 ·Status: UNKNOWN ·Phase: PHASE1
-
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia
NCT02996617 ·Status: UNKNOWN ·Phase: PHASE4
-
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
NCT07096479 ·Status: RECRUITING
-
A Study Comparing Pegylated Filgrastim and Filgrastim in Support for Chemotherapy
NCT01285219 ·Status: COMPLETED ·Phase: PHASE3
-
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
NCT03618810 ·Status: UNKNOWN
-
A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy
NCT01560195 ·Status: UNKNOWN ·Phase: PHASE3
-
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
NCT04460508 ·Status: UNKNOWN ·Phase: PHASE2
-
A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors
NCT03798665 ·Status: UNKNOWN
-
Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies
NCT04773327 ·Status: UNKNOWN ·Phase: NA
-
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
NCT02805153 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy
NCT04547829 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients
NCT01238562 ·Status: COMPLETED ·Phase: PHASE1
-
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
NCT04554056 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia
NCT02805205 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
NCT02005458 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
NCT04466137 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia
NCT01923545 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
NCT06711523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy
NCT01611051 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer
NCT03206684 ·Status: UNKNOWN ·Phase: PHASE4
-
Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC
NCT06958614 ·Status: COMPLETED
-
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
NCT04477616 ·Status: COMPLETED ·Phase: PHASE2
-
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
NCT04345900 ·Status: COMPLETED ·Phase: PHASE2